These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8841149)

  • 1. Human pharmacokinetics of dihydroergotamine administered by nasal spray.
    Humbert H; Cabiac MD; Dubray C; Lavène D
    Clin Pharmacol Ther; 1996 Sep; 60(3):265-75. PubMed ID: 8841149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.
    Shrewsbury SB; Cook RO; Taylor G; Edwards C; Ramadan NM
    Headache; 2008 Mar; 48(3):355-67. PubMed ID: 18179563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
    Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
    Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of intranasal formulations of dihydroergotamine.
    van der Kuy PH; Lohman JJ; Hooymans PM; Ter Berg JW; Merkus FW
    Eur J Clin Pharmacol; 1999 Nov; 55(9):677-80. PubMed ID: 10638398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
    Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
    Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
    Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dihydroergotamine as a nasal spray in the therapy of migraine attacks. Efficacy and tolerance].
    Jenzer G; Bremgartner MF
    Schweiz Rundsch Med Prax; 1990 Aug; 79(31-32):914-7. PubMed ID: 2203127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits.
    Marttin E; Romeijn SG; Verhoef JC; Merkus FW
    J Pharm Sci; 1997 Jul; 86(7):802-7. PubMed ID: 9232520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal delivery of antimigraine drugs: clinical rationale and evidence base.
    Rapoport A; Winner P
    Headache; 2006 Nov; 46 Suppl 4():S192-201. PubMed ID: 17078851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zelrix: a novel transdermal formulation of sumatriptan.
    Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
    Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacologic treatment of acute migraine attack in children].
    Cuvellier JC; Joriot S; Auvin S; Vallée L
    Arch Pediatr; 2005 Mar; 12(3):316-25. PubMed ID: 15734131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal absorption of rizatriptan--in vivo pharmacokinetics and bioavailability study in humans.
    Chen J; Jiang XG; Jiang WM; Gao XL; Mei N
    Pharmazie; 2005 Jan; 60(1):39-41. PubMed ID: 15702515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic comparison of prostaglandin E1 administered by different routes to rats.
    Gu FG; Cui FD; Gao YL
    Yao Xue Xue Bao; 2007 Jul; 42(7):787-93. PubMed ID: 17882966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.